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Introduction
Adipose tissue (AT) is a multifunctional organ that, beyond its 
traditional role as a lipid storage site, is pivotal in metabolic and 
endocrine health (1). Excess development of AT, however, leads 
to obesity and is a forerunner of several chronic diseases. It is esti-
mated that 38% of the world’s adult population will be overweight 
by 2030 and another 20% will be obese (2, 3). Obesity-related dis-
eases are among the fastest growing noncommunicable diseases 
today. Worryingly, the incidence of obesity is increasing among 
infants and children below 5 years of age, showing a 30% increase 
globally in the last 2 decades and a 10-fold increase in the last 4 
decades (2). This translates to 41 million obese infants and young 
children in 2016, and this is estimated to rise to 70 million in the 
next 6 years (2). Most recent studies show that obesity status in 
early childhood is a key determinant of obesity development in 
later life, and being obese as a child increases the risk of obesity- 
related diseases in adulthood (3, 4). Accordingly, childhood obesity 
is one of the most serious public health challenges of our time (5).
Recent studies show that children who are breastfed have a 
lower probability of developing obesity (6–8), but how this occurs 
remains unknown (9). Breast milk is a rich source of lipid media-
tors (10), and lipid signaling is essential for AT physiology (1, 11). 
Indeed, breast milk lipid composition is mirrored by AT lipid com-
position (12) and AT is a major source of breast milk lipids (13). 
Functions of breast milk lipid mediators have been mostly studied 
in the context of neonate immunity and the inflammatory state (8, 
14–17), and it is much less understood how breast milk–derived lip-
id signals control AT development.
Neonates are born with beige AT–dominated (BeAT-domi-
nated) AT depots, which in part support the maintenance of the 
body’s core temperature (18). BeAT shares ontogeny with white 
AT (WAT); however, it has some functional similarities to brown 
AT (BAT), such as increased mitochondrial content, multilocular 
storing of lipid droplets, and the ability to burn off lipids as heat 
due to an uncoupling mitochondrial terminal electron transport 
chain from ATP generation (18). BeAT is progressively replaced by 
WAT in late infancy and in adolescence (18, 19). This replacement 
of BeAT by WAT is accelerated in obese children (20), showing 
that premature loss of BeAT can be a cause of obesity. Along this 
line, increasing WAT/BeAT transformation in adulthood has been 
recently identified as a potential strategy for treating obesity (18, 
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in infants. To test this, we increased the AKG intake in C57BL/6 
neonate mice by approximately 20% between P3 and P10 (Fig-
ure 1D) by oral administration, using AKG-free olive oil as a vehi-
cle (Supplemental Figure 3F). Littermate controls were fed with 
vehicle. P3–P10 is an important period for determination of body 
adiposity, since BeAT starts to develop into lipid-storing WAT 
(Supplemental Figure 5A). The human equivalent of this period is 
late infancy, when intensive AT remodeling takes place (29), and 
AT mass of the young child determines obesity status in later life 
(3). BeAT content, along with Ucp1 transcription, declines further 
from P10 to adulthood in mouse (Supplemental Figure 5B).
We found that the AKG-treated group had reduced inguinal 
AT (iAT) weight (Figure 1E) and retained a BeAT-dominated iAT 
(Figure 1, F–H). Adipocyte size and triacylglycerol (TG) content 
of iAT were significantly lower in AKG-treated mice than in vehi-
cle-treated counterparts, whereas mitochondrial content, BeAT 
area, and plasma glycerol levels were significantly higher (Fig-
ure 1I), hallmarking BeAT development (30). Lean weight was 
not affected by AKGs (Figure 1I). Consistently, AKG treatment 
increased iAT transcription of Ucp1, Ppargc1a, Cox7a1, Cidea, Dio2, 
and Tmem26 (Figure 1J and Supplemental Figure 5B), which are all 
markers of BeAT (21, 31). In contrast, no changes were detected in 
the transcription of Adrb3 and its downstream targets Lipe (Hsl) and 
Pnpla2 (Atgl), which are responsible for lipolysis (Figure 1J). More-
over, AKG-treated mice challenged with hypothermia maintained 
a higher core temperature than the vehicle-treated mice (Supple-
mental Figure 5C). AKGs specifically affected iAT, the main site of 
BeAT development, whereas BAT was only moderately affected by 
AKG treatment (Supplemental Figure 5, D–G). AKGs did not affect 
weight or impose changes on other organs (Supplemental Figure 5, 
H–M). After weaning, AKG-treated mice had a reduced iAT mass, 
without changes in lean body weight (Supplemental Figure 5N).
Overall, our findings suggest that AKGs, which are taken up 
from breast milk, increase BeAT content. This raises the question 
as to whether the lack of breastfeeding impairs BeAT development. 
To test this possibility, we analyzed samples of inguinal subcutane-
ous AT from 20 human infants aged 0.2–1.0 year for UCP1 expres-
sion and BeAT content (Figure 2, A–D, and Supplemental Table 2). 
We found that if breastfeeding was the dominant nutritional source 
(Supplemental Figure 6A), UCP1 had peak levels at ages 0.2–0.3 year, 
with moderate levels from 0.4 year onwards (Figure 2A). In contrast, 
UCP1 mRNA expression was undetectable in most infants who were 
never breastfed or received negligible breastfeeding (Figure 2B, P 
= 0.0019, Mann-Whitney U test, Supplemental Table 2). Similarly, 
when we compared exclusively breastfed, partial breastfed, and nev-
er breastfed infants, we found compromised or undetectable UCP1 
levels in infants who received breastfeeding for 30% or more of their 
actual age or were never breastfed (Supplemental Figure 6A). When 
age-matched infants were compared, breastfed infants had higher 
UCP1 mRNA levels than formula-fed infants (Figure 2C; P = 0.0122, 
Mann-Whitney U test). Consistently, BeAT content was higher (Fig-
ure 2D), and mitochondria-rich, multilocular adipocytes were abun-
dant in the AT of breastfed infants (Supplemental Figure 6B).
Formula-fed infants received cow milk–based, hence AKG- 
deficient, formula, which prompted us to examine the effect of 
AKG-deficient postnatal nutrition on BeAT. For this analysis, we 
tested 3 groups of mice: one received regular breastfeeding from 
21). However, the signals that determine BeAT content and set the 
point of BeAT/WAT transformation in infancy are unclear.
We show here that a breast milk–specific lipid group, the 
so-called alkylglycerol (AKG, 1-O-alkyl-sn-glycerol) ether lipids, 
sustain infant BeAT. AT macrophages (ATMs) metabolize AKGs, 
and this activates adipocyte STAT3 signaling and triggers BeAT 
development. Lack of AKGs causes premature BeAT/WAT trans-
formation. AKGs are hence powerful mediators of breast milk and 
they establish a mother-to-child lipid signaling bridge that is piv-
otal for healthy AT development.
Results
Breast milk is the only relevant nutritional source of AKGs. AKGs of 
human breast milk are chimyl alcohol (CA), batyl alcohol (BA), and 
selachyl alcohol (SA); these are present in micromolar concentra-
tions (22–25) (Figure 1A and Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI125646DS1). Breast milk is the sole relevant source of AKGs in 
human nutrition, and it is highly improbable that a human adult 
consumes the equivalent of the daily AKG intake of a breastfed 
infant (Supplemental Figure 2, A–C). To determine whether AKGs 
are secreted into mouse’s milk, we established a nanoelectrospray 
ionization tandem mass spectrometry–based analytic technique 
(Supplemental Figure 3, A–D). Mouse milk contained AKGs in the 
micromolar range (Figure 1, B and C, and Supplemental Figure 
3E). In accordance with previous studies (22, 23), we also found 
that human milk was rich in AKGs and, similarly, canine and goat 
milk contained AKGs (Supplemental Figure 3F). In contrast, AKGs 
were negligible in cow milk, the major component of infant formu-
la (Supplemental Figure 3F).
Using the same approach, we also questioned whether AKGs 
were present in the blood plasma of neonate mice, finding that plas-
ma AKG levels mirrored those in breast milk (Figure 1C and Supple-
mental Table 1). In contrast, AKGs were absent (CA and SA) or neg-
ligible (BA) in the plasma of adult mice (Figure 1C). This suggests 
that breast milk was the source of AKGs. Consistently, when mice 
were fed AKGs, the plasma AKG level was increased, proving the 
intestinal absorption of AKGs (Supplemental Figure 3G). AKGs are 
absorbed by the lymphatic vessels of the intestine and are distrib-
uted in the systemic circulation by chylomicrons and low-density 
lipoproteins (Supplemental Figure 4A). AKGs can hence reach AT 
directly, without passing through the portal vein (Supplemental Fig-
ure 4B). This and the lipophilic nature of AKGs make it plausible that 
AKGs are deposited in AT (Supplemental Figure 4C). Accordingly, 
we found AKG accumulation in mouse and human AT (Supplemen-
tal Figure 4, D and E). While little is known about the metabolism 
of AKGs, an AKG-catabolizing enzyme, a so-called AKG-mono-
oxygenase (AGMO or TMEM195; EC 1.14.16.5), has been recent-
ly identified (26, 27). AGMO is a membrane-bound enzyme that 
cleaves AKGs into glycerol and fatty aldehyde (FA) (Supplemental 
Figure 4F) (26, 28). Transcriptional analysis of Agmo showed that 
its expression in the AKG-accumulating AT was moderate. Howev-
er, liver, which had negligible AKG content, expressed much higher 
Agmo than any other organ tested (Supplemental Figure 4, G–J).
Breast milk AKGs maintain beige adipocytes in infant AT. Our 
data show that AKG intake is confined to infancy and that AKGs 
are enriched in AT, suggesting that they may affect AT physiology 
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Figure 1. Breast milk AKGs increase beige adipocyte content in infant mice. (A) Structure of AKGs found in human breast milk. (B) Level of AKGs in 
mouse breast milk on P3 and P6 normalized to protein content. (C) Levels of AKGs in breast milk of 3 lactating mice and the plasma AKG levels of their 
respective litters on P3 and P6. One data point represents plasma pooled from 8 to 9 infant mice. Plasma AKG levels on P56. (D) Schematic of AKG treat-
ment of infant mice. (E) iAT weight on P10 of vehicle- or AKG-treated mice. (F–H) Histology of iAT. H&E staining and UCP1 immunohistochemistry (F), 
semithin sections stained with toluidine blue (G), and transmission electron microscopy of adipocytes (H). lp, lipid vesicle; mt, mitochondria; nc, nucleus. 
Arrowheads show BeAT; arrow shows fusing lipid vesicles. Scale bars: 25 μm (F and G); 5 μm (H). (I) Mitochondrial content, TG content, adipocyte size, 
BeAT area in iAT, plasma glycerol levels, and lean weight on P10. (J) Transcription of BeAT hallmark genes in iAT on P10 of vehicle- or AKG-treated mice.  
*P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA with Dunnett’s post hoc test (C) and Student’s 2-tailed unpaired t test (E, I, J).
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and AR groups along the study period (Supplemental Figure 6E). 
AR was without a notable effect on BAT development (Supple-
mental Figure 6, F and G). These findings show that deprivation 
from breast milk led to premature loss of BeAT, which was mitigat-
ed when AKGs were provided to the neonates.
AKGs induce a beige adipocyte phenotype in an ATM-dependent 
manner. To begin to understand the underlying mechanism by 
which AKGs maintain BeAT, we treated 3T3-L1 preadipocytes and 
adipocytes in vitro with AKGs, using concentrations that were com-
parable with the physiological levels in neonate plasma and iAT. 
Throughout the study, we used 100 nM CA, BA, or SA or an equi-
molar combination of the 3 AKGs for in vitro assays. AKG treatment 
failed to increase mitochondrial content or affect mitochondrial 
activity, glycerol release, or the transcription of BeAT-hallmark 
genes (Supplemental Figure 7, A–F, and Supplemental Figure 8A). 
Similarly, AKGs failed to affect BeAT gene transcription in iAT- 
derived preadipocytes (Supplemental Figure 8B).
the natural mothers; the other 2 groups were artificially reared 
(AR) with formula milk and fostered by ovariectomized, hence 
nonlactating, mice (Figure 2E). One group of AR mice received 
formula milk lacking AKGs, while the other group received 
AKG-supplemented artificial milk. We used the CD1 mouse strain 
as it is amenable to AR studies and has the added advantage that 
the BeAT/WAT transition is slower than in C57BL/6 mice (Supple-
mental Figure 6C), allowing us to accurately determine whether 
AKG deficiency reduces BeAT content.
AR compromised BeAT content and UCP1 expression, and 
this was accompanied by an increase in the TG content of the iAT 
(Figure 2, F–H, Supplemental Figure 6D). When AKG levels of the 
artificial milk were restored to their physiological range (Figure 1B 
and Supplemental Figure 3E), BeAT content, UCP1 expression, 
and TG content in the iAT were similar to those in the breastfed 
mice (Figure 2, F–H, and Supplemental Figure 6D). No differences 
in body weight and nursing volume were noted between breastfed 
Figure 2. Lack of breastfeeding and lack of neonatal AKG intake reduce beige adipocyte content in the iAT. (A–C) Color-coded CIM showing the relative 
transcript level of UCP1 in human infant iAT. Also see Supplemental Figure 6A. (A) Breastfed infants, (B) formula-fed infants; age in years and the individ-
ual identifier number are indicated for each sample. (C) CIM showing relative UCP1 level in 0.3- to 1.0-yearold infants. UCP1 level was normalized to 3 ref-
erence genes (ACTB, TBP, HPRT1), and individual values were compared with the mean value of the 2 study groups. (D) Histology and BeAT content of the 
iAT in breastfed and formula-fed human infants. Scale bars: 100 μm (H&E); 25 μm (UCP1). (E) Scheme of artificial rearing (AR) experiment. (F) Histology of 
the iAT at P10 and P34 in breastfed and AR mice. ac, white adipocyte. Scale bars: 80 μm. (G) BeAT content of the iAT at P34. (H) CIM showing relative UCP1 
level in iAT on P10 and P34. **P < 0.01; ***P < 0.001, Student’s 2-tailed unpaired t test (D); 1-way ANOVA with Dunnett’s post hoc test (G).
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mice had a similar effect on neonate preadipocytes (Supplemen-
tal Figure 8, F–H). Oxygen consumption of 3T3-L1 adipocytes was 
increased by conditioned media of AKG-treated ATMs (Figure 
3G). We labeled mitochondria with mito-thermo-yellow (MTY), 
a recently available fluorescent marker of mitochondrial ther-
mogenesis and uncoupling (37–39). Reduced MTY signal indi-
cated increased thermogenesis and uncoupling in adipocytes of 
AKG-treated neonate mice on P10 (Supplemental Figure 8I) and 
in both adult and neonate preadipocytes when they were treated 
with AKGs in the presence of adult or neonate ATMs, respectively 
(Supplemental Figure 8J).
Next we asked whether the absence of ATMs would impair 
AKG-induced transcription of BeAT-marker genes in vivo. We used 
high fat diet (HFD) feeding for 3 months to induce obesity, since it 
is known that ATM content is increased after HFD feeding in mice 
(40). We injected mice intraperitoneally with AKGs (20 μmol/kg 
CA, 3.5 μmol/kg SA, 40 μmol/kg SA) and found that Ucp1, Pparg-
c1a, and Cox7a1 were upregulated in adipocytes of the iAT within 
4 hours (Figure 3H, P < 0.01, Student′s 2-tailed, unpaired t test). 
Remarkably, when ATMs were depleted with clodronate liposomes 
24 hours prior to AKG injection, AKG treatment failed to evoke 
these transcriptional changes (Figure 3H). Overall, these findings 
suggest that ATMs are indispensable for the effect of AKGs.
It has recently been shown that ATMs may induce BeAT 
development in adulthood through mechanisms that remain 
unclear and controversial (32–34). To determine whether ATMs 
play a role in the BeAT-inducing effect of AKGs, we cultured 3T3-
L1 adipocytes in the presence of ATMs using a Transwell system 
(Figure 3A). We plated adipocytes in the bottom chamber. The 
top chamber was left unseeded or was seeded with ATMs. In the 
presence of ATMs, AKG treatment increased adipocyte mito-
chondrial content (Figure 3, B–D, and Supplemental Figure 7G). 
MitoTracker Green and Red staining of mitochondria confirmed 
that they were functional (Figure 3, B–D, and Supplemental Fig-
ure 7G), with a significantly increased relative mitochondrial 
NADH dehydrogenase (NADH-DH) activity (Figure 3E). The 
level of NADH-DH activity reflects mitochondrial respiration 
(35), which is increased in beige adipocytes (36). In the presence 
of ATMs, AKG treatment increased Ucp1 transcription in 3T3-L1 
adipocytes (Figure 3F). J774A.1 macrophages had a similar, albeit 
less conspicuous, effect on adipocytes (Supplemental Figure 7H). 
Moreover, AKGs increased Ucp1 transcription and mitochondri-
al content in preadipocytes derived from adult mouse iAT in the 
presence of ATMs, and conditioned media of AKG-treated adult 
ATMs increased mitochondrial biogenesis in preadipocytes (Sup-
plemental Figure 8, C–E). ATMs harvested from iAT of neonate 
Figure 3. Macrophages are necessary for the effect of AKGs on adipocytes. (A) Schematic of a Transwell assay with ATMs and 3T3-L1 adipocytes. (B–G) 
Adipocytes were treated with vehicle or AKGs for 24 hours, without ATMs (–ATMs) or in the presence of ATMs (+ATMs). Each data point represents 1 Trans-
well assay (B, E–G) or 1 adipocyte (D). (B) MFI of MitoTracker Green in adipocytes after treatment. (C) MitoTracker Red staining and transmission electron 
microscopy (TEM) images of 3T3-L1 cells treated in the presence of ATMs. Asterisks show lipid droplets; arrowheads show mitochondria. Scale bars: 25 μm 
(MitoTracker Red); 5 μm (TEM). (D) Mitochondrial content of 3T3-L1 cells, determined with image analysis. (E) Relative NADH-DH activity of adipocytes. 
(F) Ucp1 transcription in adipocytes. (G) Oxygen consumption of adipocytes treated with conditioned media of ATMs for 18 hours. ATMs were treated with 
vehicle or AKGs for 4 hours before cell culture media was collected and used for treating adipocytes. (H) CIM representation of BeAT-marker gene transcrip-
tion in iAT of HFD-fed mice treated with vehicle or AKGs. ATMs were depleted with clodronate liposomes 24 hours before treatment in 1 group of mice (n = 
5). (I) AT from human and M. mulatta infants, labeled for CD163 and Iba1. Scale bars: 10 μm (upper panels); 25 μm (lower panels). **P < 0.01; ***P < 0.001, 
Student’s 2-tailed unpaired t test (B, E–G) 1-way ANOVA with Dunnett’s post hoc test (D).
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We previously showed that ATMs seed AT shortly after birth 
in mice (41). ATM accumulation has been shown to occur in 
childhood obesity (42). However, it is unknown whether human 
infant AT harbors resident ATMs under physiological conditions. 
Immunohistochemistry analysis revealed CD163+ ATMs in human 
infant AT (Figure 3I and Supplemental Figure 9). CD163 is an ear-
ly marker of tissue-resident macrophages, including ATMs (43). 
Similarly, ATMs in newborn Macaca mulatta expressed ionized 
calcium-binding adapter molecule 1 (Iba1) (Figure 3I and Sup-
plemental Figure 9). Iba1 is an additional marker expressed by 
embryo-derived macrophages (44). These findings are especially 
important, since they demonstrate that ATMs are present when 
the physiologically relevant AT development of infancy occurs.
PAF mediates the effect of AKGs on BeAT development. To deter-
mine the effect of AKGs on ATMs, we performed a series of func-
tional tests and treated them with 100 nM AKGs for 18 hours. AKGs 
had no effect on ATM viability, general morphology, or phago-
cytosis (Supplemental Figure 10, A–E). Using next-generation 
sequencing (NGS), we also assessed the transcriptional changes 
induced by AKGs. Transcripts related to ether lipid metabolism, 
especially to platelet-activating factor (PAF) precursor phospho-
choline metabolites, were enriched in AKG-treated ATMs (Figure 
4A). These observations prompted us to address whether AKGs 
had any effect on macrophage PAF production. Although AKG 
metabolism is poorly understood, recent studies have outlined the 
possibility that AKGs are utilized by a multienzyme-catalyzed pro-
cess to generate PAF (15, 45), a potent phospholipid mediator (26, 
27, 46) (Figure 4B). In line with these predictions, we found that 
AKG treatment led to PAF release from mouse and human ATMs 
and that AKGs mirrored the transcriptional changes evoked by 
PAF in macrophages (Figure 4, C and D, and Supplemental Figure 
10, F–J). Human THP-1 macrophages have been shown to convert 
AKGs to PAF (45), and we confirmed this production (Supplemen-
tal Figure 10I). The magnitude of AKG-induced PAF release was 
similar to that of the calcium ionophore A23187, a known trigger 
of PAF release (Supplemental Figure 10K). The transcriptional 
changes evoked by AKGs in macrophages were dependent on the 
PAF receptor (PTAFR), as they were abolished by its inhibition or 
ablation (Supplemental Figure 11, A and B). PAF is nonenzymati-
cally converted into azelaoyl-PAF (AzPAF), which is a PPARγ ago-
nist (47). Accordingly, the effect of AKGs on Arg1 and Il4ra tran-
scription was mirrored by AzPAF and was dependent on PPARγ 
(Supplemental Figure 11, C–G).
AKG treatment failed to increase PAF release from preadipo-
cytes and adipocytes (Figure 4C). However, ATMs were abundant 
in BeAT and were in close proximity to beige adipocytes (Figure 
4, E and F, and Supplemental Figure 9), which may allow for para-
crine effects by AKG-induced PAF release on adipocytes. Accord-
ingly, depletion of ATMs in neonate mice compromised BeAT 
gene transcription in iAT, despite AKGs being provided by breast-
feeding (Supplemental Figure 8K).
AKGs are structurally similar to 1-O-alkyl-2-acetyl-sn-glycer-
ols (AAGs), which are substrates of de novo PAF synthesis, and to 
lyso-PAF, which is a substrate for PAF synthesis by phospholip-
id remodeling (Supplemental Figure 12). We evaluated whether 
genes encoding key enzymes of PAF synthesis from AAGs or lyso-
PAF were expressed by ATMs. We found that Chpt1, encoding 
choline phosphotransferase 1 (CHPT1, EC: 2.7.8.2), an enzyme 
that is responsible for de novo PAF synthesis from AAGs, was 
absent from mouse ATMs. However, it was robustly expressed 
by mouse adipocytes (Figure 4G). In contrast, Lpcat2, encoding 
lyso-PAF acetyltransferase 2 (LPCAT2, EC: 2.3.1.23), was mainly 
expressed by ATMs and was much less abundant in adipocytes 
in mouse (Figure 4G and Supplemental Figure 13A). LPCAT2 is 
known to remodel lyso-PAF into PAF (48). Protein expression of 
CHPT1 was confined to adipocytes in both mouse and human 
(Figure 4, G and H). LPCAT2 was detectable in mouse and 
human ATMs and to a lesser extent in adipocytes (Figure 4, G and 
H). PLA2G2A and PLA2G10 (phospholipase 2 group IIA and X, 
respectively, EC 3.1.1.4) can generate substrates for PAF remod-
eling. PLA2G2A was, however, not detectable in either ATMs or 
adipocytes in mouse (Supplemental Figure 13A), in accord with 
previous findings showing a frame-shift mutation in Pla2g2a in 
C57BL/6 mice (49). Human ATMs, but not adipocytes, howev-
er, expressed PLA2G2A (Supplemental Figure 13A). PLA2G10 
was abundant in mouse adipocytes (Figure 4G), although human 
ATMs or adipocytes did not express it (Supplemental Figure 13A). 
PLA2G10 activity leads to the release of PAF, prostaglandin E2 
(PGE2), and 15-deoxy-delta12,14-prostaglandin J2 (PGJ2) by the 
hydrolysis of membrane phospholipids (50–52). Prostaglandins 
are thought to induce BeAT development (53); however, AKG 
treatment failed to induce PGE2 or PGJ2 release from ATMs 
(Supplemental Figure 13B). These findings suggest that AKGs act 
specifically through PAF.
Next, we assessed the expression of PAF-catabolizing enzymes 
in ATMs and adipocytes. PLA2G7, also known as PAF acetylhydro-
lase (PAF-AH, EC 3.1.1.47) degrades PAF (28), and its expression 
was prominent in mouse and human ATMs (Figure 4, G and H). In 
contrast, AGMO, which degrades AKGs and reduces the substrate 
pool for PAF synthesis (27), was expressed by adipocytes, while 
ATMs had only minor AGMO expression (Figure 4, G and H, and 
Supplemental Figure 4J). When we cultured mouse ATMs and adi-
pocytes in vitro, we found a similar expression pattern: LPCAT2 
and PLA2G7 were expressed by ATMs only, while PLA2G10 and 
AGMO were detectable in adipocytes only (Figure 4I). Of note, in 
vitro–cultured ATMs had much lower AGMO levels than fresh-
ly isolated ATMs (Supplemental Figure 13C). This suggests that 
AT-specific cues sustained AGMO level in ATMs.
Inhibition of LPCAT2 resulted in the absence of AKG-induced 
PAF release from ATMs (Figure 4J), whereas overexpression of 
LPCAT2 increased AKG-induced PAF release (Supplemental Fig-
ure 10, L and M). Other inhibitors of PAF remodeling diminished, 
but did not abolish, PAF synthesis from AKGs (Figure 4J). In sum-
mary, these results show that ATMs, but not adipocytes, metabo-
lize AKGs toward PAF (Figure 4K).
PTAFR is expressed in developing AT (Supplemental Figure 
13D), where it has been shown to induce BeAT development (54). 
Additionally, Ucp1 is directly upregulated by PAF in brown adipo-
cytes (55). Accordingly, BeAT was absent from Ptafr–/– mice, which 
also accumulated more TGs in the iAT than WT mice (Figure 5A 
and Supplemental Figure 13E). When we increased endogenous 
PAF synthesis in C57BL/6 mice by overexpressing human PLA-
2G2A (49), we found a robust increase in the BeAT content (Figure 
5B and Supplemental Figure 13, F–H).
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Figure 4. ATMs release PAF in response to AKGs. (A) NGS of vehicle- or AKG-treated macrophages. AKGs enriched transcripts related to phosphatidylcho-
line (PC) and lyso-PC metabolism. Pink bars, relative abundance of GO terms (combined score rankings). (B) AKGs can serve as backbones of the sn-acyl 
chain of PAF. (C) Top: PAF levels in cell culture media of 3T3-L1 pre-/adipocytes or ATMs treated with vehicle or AKGs for 30 minutes. Bottom: PAF release 
from 6-day-old neonate (P6) mouse preadipocytes (Pre-ACs), adipocytes (ACs), and ATMs in 30 minutes. (D) AKG-, and PAF-induced transcriptional 
changes in ATMs. (E) F4/80+ ATMs in mouse on P10. Scale bar: 10 μm. (F) TEM image of mouse BeAT on P10. lp, lipid droplet. Scale bar: 4 μm. Arrow shows 
an ATM-like cell. (G) Transcript levels (left) and FACS analysis (right) of PAF-metabolizing enzymes in mouse ATMs and adipocytes. Iso, isotype control (H) 
FACS analysis of PAF-metabolizing enzymes in human ATMs and adipocytes. (I) Immunostaining of mouse ATMs and adipocytes cultured in vitro. Scale 
bars: 10 μm. (J) Effect of PAF synthesis inhibitors on AKG-induced PAF release in macrophages. FRS, farnesol (CHPT1 inhibitor); TSI-01, LPCAT2 inhibitor; 
LY315920 and 12777, PLA2 inhibitors. **P < 0.01; ***P < 0.001, Student’s 2-tailed unpaired t test. #P < 0.05; ###P < 0.001, 1-way ANOVA with Dunnett’s 
post hoc test. (K) Schematic of AKG metabolism in adipocytes and ATM.
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mitochondrial load (Figure 5C and Supplemental Figure 13I). In 
the presence of ATMs, however, PAF increased the mitochondrial 
load of adipocytes (Figure 5, D and E), an effect that was dimin-
ished when PTAFR was pharmacologically inhibited (Figure 5E). 
AKGs induced IL-6 release from ATMs (Supplemental Figure 13J), 
which effect was mediated by PAF/PTAFR (Supplemental Figure 
11A). When we treated adipocytes with 0.2 ng/ml IL-6 — mimick-
ing AKG-induced IL-6 release from ATMs — the transcription of 
Given that these data suggest that PAF release from AKGs may 
be a trigger for BeAT development, we next addressed the potential 
underlying signal mechanisms. PAF induces p38-MAPK phosphor-
ylation (56), which is required for Ppargc1a and Ucp1 transcription 
(57). However, conditioned media of AKG-treated ATMs failed to 
induce p38-MAPK phosphorylation in adipocytes (Supplemental 
Figure 13I). More surprisingly, PAF treatment of 3T3-L1 adipocytes 
failed to induce the transcription of BeAT-marker genes or increase 
Figure 5. AKG-induced BeAT development is mediated by PAF/IL-6/STAT3 signaling. (A) Histology at P7 and P10; BeAT and TG content of AT at P10 in WT 
and Ptafr–/– mice. Arrowheads show BeAT. Scale bars: 65 μm. (B) PAF and BeAT content of AT at P10 and AT histology at P7 and P10 in WT and Pla2g2a-Tg 
(PLA2G2A-overexpressing) mice. Scale bars: 80 μm. (C) Relative transcription of Ucp1 and Ppargc1a in 3T3-L1 adipocytes treated with vehicle, 50 nM PAF, 
or carbamyl PAF (Carb-PAF) for 18 hours. (D) MitoTracker Red staining and TEM image of 3T3-L1 adipocytes treated with conditioned media of ATMs for 18 
hours. ATMS were treated with vehicle or 50 nM PAF. See also Supplemental Figure 7G. Arrowheads show mitochondria. Scale bars: 5 μm. (E) Mitochon-
drial content and MFI of MitoTracker Green labeling of 3T3-L1 adipocytes treated with vehicle or 50 nM PAF for 18 hours in the presence of ATMs. SR27417, 
PTAFR blocker. (F) Transcription of BeAT genes in adipocytes treated with 0.2 ng/ml IL-6 or 50 pg/ml TNF-α for 18 hours. (G) Transcription factor–binding 
site analysis of BeAT genes. (H) STAT3 phosphorylation in adipocytes treated with vehicle or AKGs for 30 minutes in Transwell assay shown in Figure 3A. (I) 
ATMs were treated with vehicle (Veh) or AKGs for 4 hours, and culture media were added to adipocytes for a further 18 hours. CIM summarizes transcrip-
tional changes evoked in adipocytes. STAT3 was inhibited with 500 nM cucurbitacin I, JAK/STAT3 with 280 nM ruxolitinib. (J) Schematic of the mechanism 
by which AKGs trigger BeAT gene transcription in adipocytes. **P < 0.01; ***P < 0.001, Student’s 2-tailed unpaired t test.
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AKGs do not affect adult lean AT, but induce BeAT development 
in obese AT. We next tested to determine whether AKG supplemen-
tation could prolong the existence of BeAT after breastfeeding is 
discontinued. To do this, we fed lean 10-week-old male C57BL/6 
mice with an AKG-rich diet (16 μmol/kg/d CA, 2.6 μmol/kg/d BA, 
30 μmol/kg/d SA) for 1 month. Contrary to our expectation, tran-
scription of BeAT-associated genes remained unaffected in the iAT 
(Figure 6A). This unexpected result prompted us to ask whether 
AKGs induce BeAT development in obesity. We fed C57BL/6 mice 
a HFD for 3 months and then treated them with vehicle or with 
AKGs (16 μmol/kg/d CA, 2.6 μmol/kg/d BA, 30 μmol/kg/d SA) for 
an additional month. Subsequently, AKG treatment upregulated 
BeAT genes in iAT, including Ucp1, Ppargc1a, Cox7a1, Cidea, Dio2, 
and Tmem26 (Figure 6A and Supplemental Figure 14A). We also 
detected a moderate increase in the transcription of Adrb3 and its 
downstream targets Lipe and Pnpla2. Furthermore, iAT mass and 
adipocyte size were reduced (Supplemental Figure 14, B and C) and 
BeAT genes (Ucp1, Ppargc1a, Cidea, Dio2, Tmem26) was marked-
ly upregulated (Figure 5F and Supplemental Figure 8L). Cox7a1, 
which has been recently found dispensable for BeAT (58), was not 
upregulated by IL-6 (Figure 5F). AKGs caused a moderate TNF-α 
secretion from ATMs (Supplemental Figure 13J), which, however, 
did not affect BeAT gene transcription (Figure 5F).
IL-6 can act through STAT3 (36). Ucp1, Ppargc1a, Cidea, 
Cox7a1, Dio2, and Tmem26 have binding sites for STAT3 and 
STATs upstream of their promoters (Figure 5G). AKGs induced 
STAT3 phosphorylation in 3T3-L1 adipocytes, when ATMs were 
present (Figure 5H). Conditioned media from AKG-treated ATMs 
induced BeAT gene transcription in adipocytes, which effect was 
abolished by STAT3 or JAK/STAT3 inhibition (Figure 5I). Togeth-
er, our data show that PAF lacks a direct BeAT-inducing effect. 
However, by acting through an autocrine loop, it increases IL-6 
release from ATMs, which ultimately evokes beige adipocyte dif-
ferentiation (Figure 5, I and J).
Figure 6. Effects of dietary AKG supplementation in obesity. (A) Transcript levels of BeAT genes and genes associated with adipogenesis and lipolysis in 
iAT of lean, and HFD-fed mice, treated with vehicle or AKGs. (B) Histology and UCP1 immunohistochemistry of iAT of HFD-fed mice treated with vehicle 
or AKGs. Scale bars: 50 μm. (C) Transcript levels of BeAT genes and genes associated with adipogenesis and lipolysis in iAT of Leprdb/db mice treated with 
vehicle or AKGs. (D) Weight gain within 1 week, iAT weight, and TG content of iAT of Leprdb/db mice treated with vehicle or AKGs. (E) Histology, (F) adipocyte 
size, and (G) plasma glycerol level in Leprdb/db mice treated with vehicle or AKGs. Scale bars: 50 μm (H&E); 10 μm (UCP1). Arrowheads show UCP1+ adipo-
cyte. (H) NGS analysis of vehicle- and AKG-treated ATMs, showing relative abundance of transcripts. Pink bars, combined score ranking of GO terms. Venn 
diagram of AKG-suppressed interferon-responsive genes, clustered according to the type of interferon response. (I) Crown-like structures (CLSs) in iAT of 
Leprdb/db mice treated with vehicle or AKGs. Scale bars: 50 μm. Quantification of CLSs in iAT of Leprdb/db mice treated with vehicle or AKGs. *P < 0.05;  
**P < 0.01; ***P < 0.001, Student’s 2-tailed unpaired t test.
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exchange rate (RER) (Supplemental Figure 14H). This decrease 
of RER, together with a marked decrease in iAT, reduced adi-
pocyte size, and increased BeAT gene transcription (Figure 6, A 
and B, and Supplemental Figure 14, A–C), indicates an increased 
oxidation of lipids in response to AKGs. AKGs did not affect met-
abolic rate and energy expenditure substantially (Supplemental 
Figure 14H), which suggests that loss of fat mass was not a result 
of increased activity. In summary, AKG treatment induced BeAT 
and reduced iAT mass in obese mice. However, AKGs remained 
ineffective in lean adult animals.
AKG-induced BeAT development is inactivated in adulthood. 
BeAT development is associated with increased mitochondrial 
content and uncoupling, which can have unfavorable outcomes 
when it occurs in excess (63, 64). The expansion of the mito-
chondrial network is thus maintained in a physiological range by 
signals that remain the subject of intense research (65, 66). It is 
intriguing that AKGs had an effect only in neonates and in adult 
obese mice and were ineffective in lean adult mice. Thus, we 
searched for a mechanism that could inactivate AKG signaling in 
the adult, lean state. The polarization state of ATMs is known to be 
different in lean and obese AT (67). Lean AT harbors ATMs, which 
have similarities to proresolving, so-called M2 macrophages (40). 
Conversely, obesity evokes a specific activation state of ATMs that 
UCP1+ adipocytes were abundant within the iAT of the AKG-treat-
ed mice (Figure 6B). The effect of AKGs in epididymal AT (eAT) 
and BAT was not apparent (Supplemental Figure 14D). Similarly, 
when we treated leptin-resistant diabetic obese Leprdb/db mice with 
AKGs (16 μmol/kg/d CA, 2.6 μmol/kg/d BA, 30 μmol/kg/d SA) 
for 1 month, the transcription of BeAT genes was strongly upreg-
ulated in the iAT (Figure 6C and Supplemental Figure 14A). More-
over, weight gain, iAT weight, and TG content were all reduced 
in these mice (Figure 6, D–F) without a prominent effect on eAT 
(Supplemental Figure 14, E and F). BeAT development is inhibited 
by leptin resistance (59); however, we detected an increase in mito-
chondrial DNA content of iAT after AKG treatment (Supplemental 
Figure 14G), and UCP1+ adipocytes were detectable in the iAT of 
AKG-treated mice (Figure 6E) along with a reduced adipocyte size 
(Figure 6F) and increased plasma glycerol level (Figure 6G).
NGS analysis showed that AKG treatment suppressed the 
transcription of interferon-inducible genes in ATMs (Figure 6H). 
The effect of PAF was detectable by specific changes in the tran-
scription of macrophage activation genes; however AKGs did not 
polarize macrophages (Supplemental Figure 11, C–G). AKG treat-
ment also reduced the amount of crown-like structures (Figure 
6I), which are sites of inflammatory ATM activation (60–62). Indi-
rect calorimetry indicated that AKGs decreased the respiratory 
Figure 7. AKG-mediated signaling to adipocytes is inactivated at BeAT/WAT transition. (A) ATMs were treated with vehicle or AKGs for 30 minutes, 
and PAF levels were measured in the cell culture media. ATMs were pretreated with vehicle or 10 ng/ml IL-4 for 18 hours. (B) Transcript levels of Agmo in 
mouse ATMs isolated at P3, P7, P14, and P56. One data point represents pooled ATM samples from 9 to 11 neonate (P3, P7, P14) and 3 to 4 adult (P56) mice. 
##P < 0.01, 1-way ANOVA with Dunnett’s post hoc test. (C) FACS histogram showing ATM expression of AGMO and LPCAT2 at P3 and P56 and following 
3-months HFD feeding in mouse. (D) Plasma NPFF levels in C57/BL6 mouse at P3 and P10 and at weaning. **P < 0.01, Student’s 2-tailed unpaired t test. 
(E) Left: effect of NPFF on Agmo transcription in ATMs and 3T3-L1 adipocytes. Cells were treated with vehicle or 1 nM NPFF for 18 hours in vitro. Another 
data set of NPFF-induced transcriptional changes in macrophages has been published previously (62) (GEO GSE90658). Right: NGS analysis of 3T3-L1 
adipocytes treated with vehicle or NPFF for 18 hours. Ontology of significantly upregulated transcripts (P < 0.001) is shown. Pink bars, combined score 
ranking; gray bars, rank-based ranking of GO terms. TEM images of 3T3-L1 adipocytes treated with vehicle or 1 nM NPFF for 18 hours. Arrowheads show 
mitophagosome membranes. mb, multilamellar body. Scale bars: 5 μm; 1 μm (insets). (F) Schematic of AKG-mediated signaling in AT. (a) Breast milk 
AKGs are metabolized by ATMs into PAF. (b) In an autocrine loop, PAF triggers IL-6 release from ATMs. (c) The secreted IL-6 activates adipocyte JAK/STAT3 
signaling. (d) This triggers BeAT gene transcription and prevents a premature BeAT/WAT transition. (e) Under physiological conditions, AKG signaling in AT 
is active only in infancy and is inactivated in lean adult AT.
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ing mitophagy (65). Accordingly, NPFF-treated 3T3-L1 adipo-
cytes contained a greater number of mitophagosomes than vehi-
cle-treated adipocytes (Figure 7E). The adipocyte effect of NPFF 
was due to its binding to NPFFR1, which was expressed by 3T3-L1 
adipocytes (Supplemental Figure 15I). Autophagy allows metabol-
ic adaptation (72), and it coordinates with mitochondrial biogen-
esis to maintain healthy metabolism (65, 66, 73).
Our study shows that breastfeeding provides AKGs for neo-
nate ATMs, which in turn sustain BeAT (Figure 7F). The transition 
from neonate type BeAT to adult-type WAT is associated with the 
inactivation of AKG signaling, at least in part due to the M2-like 
polarization of ATMs in the lean AT. In infancy, AKG signaling is 
critical for protection from obesity, since a premature loss of BeAT 
can cause WAT excess (3, 20) (Figure 7F).
Discussion
Lipid signaling is essential for AT physiology (1, 11) and also dic-
tates the metabolic outcome of ATM functions (1, 11, 74). Breast 
milk, the most natural nutrient for infants, is a rich source of lip-
id mediators (7, 10). For instance, breast milk lipids support the 
infant’s immune functions (14–16), and alterations in breast milk 
lipids can cause chronic inflammatory diseases in the infant (8, 16, 
17). Most of the breast milk lipids are also provided in the adult 
diet (10); hence, their effect may not be specific for infancy. Here 
we show that AKGs are breast milk–specific signals, which protect 
from obesity and maintain BeAT in infants. To our knowledge, this 
is the first identified maternal lipid signal mechanism that has a 
direct impact on BeAT development.
AKGs are metabolized by ATMs, which in turn facilitates the 
local release of IL-6 in the vicinity of adipocytes and induces 
their differentiation into BeAT through JAK/STAT3. This ATM- 
adipocyte signaling is active only in early postnatal life, when 
BeAT makes up the majority of the developing AT. AKG signaling 
is hence active during a sensitive period of AT development, and 
this determines obesity status in later life (3).
Local PAF production by ATMs is the first element of AKG 
signaling. Macrophage-derived PAF is central to host defense 
(15, 75, 76). In the context of AT health, PAF was hence initially 
considered as a metabolically nonfavorable mediator, since it can 
trigger AT inflammation (48). Supporting this scenario, the lack 
of PTAFR protects mice from diet-induced AT inflammation (55). 
However, the absence of PTAFR also increases lipogenesis (55), 
and PTAFR-deficient mice develop age-related obesity and are 
more susceptible to diet-induced obesity than WT mice (54, 77, 
78). Conversely, mice overexpressing human PLA2G2A, a major 
enzyme of PAF remodeling, are protected from diet-induced obe-
sity and present increased thermogenesis (49). BAT function is 
also impaired in PTAFR-deficient mice, due to the lack of PAF- 
induced upregulation of Ucp1 mRNA in brown adipocytes (54, 
77). It has also been shown that the plasma level of PLA2G7 posi-
tively correlates with the degree of abdominal obesity in children 
(79). Since PLA2G7 eliminates PAF (80) and obese children have 
compromised BeAT content (20), it is possible that PAF signaling 
impedes obesity development in children. This would be consis-
tent with our findings showing a function for PAF/PTAFR sig-
naling in maintaining BeAT. Reinforcing this notion, ablation of 
PTAFR led to the absence of BeAT, whereas increasing the levels 
resembles features of inflammatory, so-called M1 macrophages 
(40, 67). Because ATM activation has an impact on AT function, 
we asked whether it could affect the responsiveness of ATMs to 
AKGs. We induced M1 and M2 polarization in vitro and found that 
transcription of Lpcat2 and Pla2g10, which are encoding enzymes 
involved in AKG/PAF conversion and PAF remodeling, respec-
tively, was increased by M1 polarization (Supplemental Figure 15, 
A and B). In contrast, M2 activation reduced their transcription, 
increased PAF elimination to lyso-PAF (Supplemental Figure 
15, A and B), and abolished AKG conversion to PAF (Figure 7A). 
It is known that Agmo transcription is diminished by M1-activat-
ing stimuli (26, 62) (Supplemental Figure 15, C and D), whereas 
M2 polarizing signals increase Agmo transcription in ATMs (62). 
Accordingly, we found that IL-4/STAT6 signaling controlled Agmo 
transcription and AGMO was expressed and localized to intracel-
lular membranes in IL-4–treated macrophages (Supplemental Fig-
ure 15, E and F), which serve as the site of AKG accumulation and 
PAF synthesis (24, 28, 68, 69).
AGMO effectively reduces the substrate pool for PAF synthe-
sis (26, 27) and thus has the potential to diminish the effects of 
AKGs. Accordingly, when we overexpressed Agmo in J774A.1 mac-
rophages, the AKG-induced PAF release, as well as the AKG-in-
duced Tnfa and Il6 expression, was abolished (Supplemental 
Figure 15G). We also found a striking difference in the expression 
of AGMO between neonate and adult ATMs. ATM expression of 
Agmo increased progressively in neonate mice, reaching a peak at 
P14 (Figure 7B). In neonate mice AGMO+ ATMs were scarce (Fig-
ure 7C) and only self-renewing or IL-4–treated ATMs had signifi-
cant AGMO expression (Supplemental Figure 15H). AGMO+ ATMs 
were detectable in adults, and in contrast, AGMO+ ATMs were 
undetectable in obese mice, which was similar to what occurred in 
neonates (Figure 7C). In contrast, LPCAT2 was steadily expressed 
by ATMs throughout life (Figure 7C).
We have recently shown that ATM-specific expression of 
AGMO is increased by neuropeptide FF (NPFF), which is an 
endocrine signal for homeostatic maintenance of the ATM pool 
and which increases the enrichment of M2-like ATMs in adult AT 
(62). NPFF increases AGMO expression through NPFF receptor 
2 (NPFFR2) by sustaining IL-4/STAT6 signaling (62). NPFFR2 is 
the main receptor for NPFF in AT (70, 71), and its expression is 
restricted to ATMs (62). We found that the plasma concentration 
of NPFF in neonate mice was negligible and increased at wean-
ing (Figure 7D). The similarity in the timing of changes in plasma 
NPFF levels and BeAT/WAT transition suggests that activation 
of NPFF/NPFFR2 signaling at weaning is one signal that increas-
es AGMO expression in ATMs (Figure 7E) and eventually inacti-
vates AKG effects.
Finally, we asked whether NPFF could have an ATM-inde-
pendent effect on BeAT/WAT transition. We treated 3T3-L1 adi-
pocytes with NPFF in vitro and measured changes in gene tran-
scription by NGS. We found that the effect of NPFF on adipocytes 
was strikingly different from its effect on ATMs: whereas NPFF 
sustained STAT6 signaling and inhibited various inflammatory 
pathways in ATMs (62), in adipocytes, it induced the prominent 
expression of Park2 in addition to lysosome-associated transcripts 
(Figure 7E). Park2 encodes parkin, a ubiquitin ligase that has 
recently been shown to allow BeAT/WAT transition by increas-
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whether development of these fat depots is affected by breast-
feeding. Surgical interventions are, however, rarely performed in 
the cervical and the interscapular regions in infancy (20), limiting 
the possibility of performing a comparative analysis. The develop-
mental origin of BAT and BeAT is distinct (18, 19), and our study 
also suggests that AKGs lack an effect on BAT. This may be due 
to the scarcity of ATMs in BAT (41) or, alternatively, to differenc-
es in AKG metabolism in BAT, WAT, and BeAT. A negative cor-
relation between BeAT content and obesity has been shown in 
children (20). Follow-up of the patients enrolled in our study can 
provide valuable information on whether this negative correlation 
is a late-acting effect of insufficient breastfeeding. In addition, a 
recent study suggests that breastfeeding protects infants from the 
development of metabolic diseases through the establishment of a 
healthy intestinal microbiota (93). Because AKGs increase Lacto-
bacillus proliferation (94), they might also contribute to this indi-
rect metabolic effect of breastfeeding.
Today nearly 60% of infants are never breastfed (95, 96) and 
childhood obesity may have its origins, at least in part, in insuffi-
cient breastfeeding (6–8, 97). Components of the manufactured 
infant formula might also be responsible for the negative meta-
bolic impact of the absence of breastfeeding (98). Moreover, cer-
tain miRNA species enriched in cow milk — the main component 
of infant formula — inhibit BeAT development (99). Against this 
background, we show that maternal AKGs are the key signals for 
healthy BeAT development and that ATMs play an essential role in 
mediating this mother-to-child lipid signaling.
Methods
Animals. We used C57BL/6, male Leprdb/db mice (Charles River Lab-
oratories) and CD1 mice (CLEA Japan Inc.). Ptafr–/– and Pla2g2a-Tg 
mice were developed as described previously (49, 77). For treatments, 
we used AKGs (CA and SA from Nippon Chemicals; BA from Mer-
ck Sigma-Aldrich), dissolved in AKG-free sterile olive oil. Mice were 
treated daily with vehicle or AKGs by oral administration. We used lit-
termates for vehicle and AKG treatment. To induce obesity, we used 
a HFD as described previously (62), and AKGs were provided in the 
diet for the treatment group. To deplete ATMs, we used intraperito-
neal injection of clodronate-filled liposomes (Clodronate Liposomes) 
as described previously (100). As a control, we used PBS-filled lipo-
somes. AT samples from nonhuman primate Macaca mulatta infants 
(n = 3) were provided by the Wisconsin National Primate Research 
Center (Madison, Wisconsin, USA). Canine breast milk samples were 
provided by a veterinary clinic in Budapest; goat and cow milk were 
purchased from commercial sources.
Human samples. Subcutaneous iAT from human infants was col-
lected in the Leipzig Childhood Adipose Tissue cohort during elec-
tive surgery (42) (ClinicalTrials.gov NCT02208141). Infants were 
assigned to breastfed or formula-fed groups after ROC analysis (Sup-
plemental Figure 6A). Duration of breastfeeding (as a percentage of 
age) was used as a predictor variable, and the optimal cut-off for group 
assignment was estimated by means of the Youden index using the 
Optimal Cutpoints package of R software (www.r-project.org). For all 
children included in the study, written informed consent was obtained 
from the parents.
Cell culture and FACS. Primary mouse and human ATMs, pread-
ipocytes, and adipocytes were isolated by collagenase digestion and 
of PAF via PLA2G2A overexpression resulted in an overwhelming 
BeAT content in neonate mice (49, 50).
We found that IL-6 was the downstream mediator of PAF, 
which activates the transcriptional program of BeAT development 
through STAT3. ATM-derived IL-6 has long been considered a del-
eterious cytokine, which together with other inflammatory medi-
ators triggers systemic metabolic disease. However, mice with 
global loss of IL-6 develop insulin resistance (81) and are more 
prone to diet-induced obesity (82). IL-6 activates mitochondrial 
biogenesis in AT (82), increases pancreatic insulin secretion (83), 
and plays a role in the hypothalamic control of appetite (84). It has 
also been shown that AT development and remodeling are criti-
cally dependent on inflammatory signaling early in postnatal life 
(85). Most recently, β3 adrenergic stimulation of lipolysis has been 
shown to trigger IL-6/JAK/STAT3 signaling and promote beige 
adipocyte development (36). Our findings on the role of AKG/
PAF/IL-6/STAT3 signaling in BeAT development are in line with 
these recent findings and confirm that BeAT development in the 
infant requires transient inflammatory signaling (86). In adult AT, 
M2 polarization of ATMs has been shown to increase BeAT content 
(32, 87), although the necessity of M2-activated ATMs for WAT/
BeAT transformation has been recently challenged (33). Since M2 
polarization suppresses the ability of ATMs to synthesize PAF from 
AKGs, it suggests that M2 ATMs play a role in BeAT differentia-
tion in cold-stressed adult AT (88), rather than in the developing 
neonate AT. These findings expand the known metabolic role of 
inflammatory ATMs (11). Moreover, ATM number is decreased in 
lean young adults (89), and the majority of ATMs adopt an M2-like 
activation state in the adult lean AT (11). The low ATM number and 
the prevalence of M2 activation can impede the effect of AKGs in 
lean adults and limit the physiological impact of AKGs on infancy.
The reason that AKGs are specifically enriched in the breast 
milk is explained by the lipid secretion mechanism of the mammary 
gland cells. Lipid vesicles are released together with the apical cell 
membrane by so-called apocrine secretion (10). AKGs are enriched 
in the apical cell membrane of the lactating gland cells (24) and 
synthesized within the cell membranes due to remodeling of other 
ether lipids (24, 28, 68, 69); hence, apocrine secretion allows AKG 
enrichment in the milk. Cow milk contains negligible AKGs, which 
is at odds with the finding of AKG synthesis and release in cow 
colostrum and milk (68). This may be due to an increased catabo-
lism of AKGs in cow milk (24). Moreover, the amount of milk pro-
duced daily by a dairy cow is magnitudes higher than of the other 
species tested and may lead to the dilution of AKG concentration to 
a negligible level. Importantly, in bovine neonates, the subcutane-
ous AT is free from BeAT, whereas other mammalian species have 
BeAT during the period of breastfeeding (90). This also suggests 
that breast milk AKGs are direct signals of BeAT development and 
that the lack of AKGs is mirrored by the lack of BeAT.
We observed a marked decrease in BeAT content and UCP1 
transcription in the inguinal subcutaneous fat compartment in 
human infants when breastfeeding was limited or absent. BeAT 
has previously been reported in subcutaneous and visceral fat 
depots in children (20). Supraclavicular, cervical, and interscapu-
lar regions also contain BeAT-rich fat depots (91), which are often 
considered to be BAT (21, 92). Because these fat depots have a 
metabolic role in adolescence (92), it is intriguing to question 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 4 9 7jci.org   Volume 129   Number 6   June 2019
Statistics. Data are represented as mean ± SEM, along with each 
individual data point. When data are represented as CIMs to visual-
ize gene transcription differences among experimental conditions, 
we indicate transcript levels relative to reference genes, fold changes 
evoked by specific treatments, or Z-scores of the relative abundance of 
the transcripts, as indicated in the figures. The applied statistical tests 
are indicated in the figure legends; P < 0.05 was considered significant.
Study approval. Human study protocols were approved by the eth-
ics committees of the University of Leipzig (265-08-ff; NCT02208141) 
and the University of Ulm (79/18, 368/18). Adult AT was collected for 
a previous study (62) and under ethical approval of the University of 
Hannover, Hannover, Germany (3475-2017). Animal experiments 
were approved by local ethical committees (NPHC, PE/EA/2010-
1/2016; Regional Council, Tübingen, Germany, 1206, O.189-20, 
O.232-1, 1398, O.232-2, 1441; Azabu University, 180112-3; University of 
Tennessee IACUC, 18-019.0-A; Wright State University IACUC, 1075).
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of macrophages was tested by fluorescent latex beads, as described 
before (103). Preparative cell sorting and FACS analysis of ATMs was 
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ence. Primer sequences are provided in Supplemental Table 3. NGS 
analysis was carried out on the BGISEQ-500 platform by BGI Genom-
ic Services, generating on average about 26.20 M reads per sample. 
After reads filtering, clean reads were mapped to the reference genome 
using HISAT. On average, 96.09% reads were mapped (Supplemen-
tal Figure 16, A and B), and clean reads were mapped to reference 
transcripts using Bowtie2, then gene expression levels for each sam-
ple were calculated with RSE. For annotation of transcripts we used 
EnrichR (104, 105) and Interferome 2.0 (106); clustered image maps 
(CIMs) were rendered by CIMminer (107). NGS data were deposited 
in the NCBI’s Gene Expression Omnibus database (GEO GSE125405).
Histology and image analysis. Tissues were fixed in 4% PFA and 
embedded into paraffin as described (62). Immunohistochemistry 
against UCP1 and F4/80 antigen was performed on paraffin-em-
bedded sections (Supplemental Figure 16, C–F). Antibodies are list-
ed in Supplemental Table 3. H&E and PAS staining were performed 
according to the manufacturer’s instructions (Carl Roth). BeAT area 
was measured with our custom-designed software; adipocyte size was 
measured with ImageJ (NIH) (Supplemental Figure 16, G and H).
Supplemental methods. AKG determination, AR, ELISAs, overex-
pression studies, indirect calorimetry, the oxygen consumption test, 
Western blotting, and TEM analysis are detailed in Supplemental 
Methods and Supplemental Tables 4–6. Full, uncut gels are available 
in the supplemental material.
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